Lilac Therapeutics
- Biotech or pharma, therapeutic R&D
Lilac Therapeutics is a clinical-stage biopharmaceutical company developing Phase 2 asset LLX-424 for diseases associated with excess oxalate, including kidney stones, CKD, kidney allograft rejection, and MASLD/MASH. Lilac is an ARCH portfolio company founded in 2020 by Manoj Desai, former head of Medicinal Chemistry and Drug Metabolism at Gilead Sciences. Lilac is chaired by Jay Parrish, who is currently a Venture Partner with ARCH Venture Partners and CEO of Pretzel Therapeutics. Lilac is led by CEO Erik Mogalian, an experienced R&D leader formerly of Gilead Science and Vir Biotechnology and who has a track record of delivering products to patients, including multiple blockbusters. The Lilac team is staffed with industry veterans who have moved LLX-424 (and Lilac) from idea to its current state in Phase 2.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}